



## Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT® Code Change Applications February 2026 Editorial Panel Meeting

Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications (CCAs) that have been submitted for consideration by the CPT Editorial Panel at its February 2026 meeting are listed below. These applications will also be included in the proposed Panel agenda that will be posted to the AMA website on December 5, 2025. This listing includes the code application names, code(s) affected, and a description of the request. **Until such time as the CPT Editorial Panel acts on these requests, the following information is provided for informational purposes only, giving interested individuals the information to help determine whether or not to attend the meeting and provide comment on a given topic(s).**

This listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP applications is being posted ahead of the full February Panel meeting agenda in order to provide the Molecular Pathology Advisory Group (MPAG) and the Pathology Coding Caucus (PCC) sufficient time to review comments from interested stakeholders prior to making their recommendations to the CPT Editorial Panel.

Codes that contain an 'X' (e.g., 10X24, 23X42, 03X0T) below are temporary codes that are intended to give readers an idea of the proposed placement in the code set of the potential code changes. **These temporary codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed on August 31<sup>st</sup> of each year. To report the services described by the "X" codes listed on this form, please refer to the actual codes as they appear in the CPT Datafiles publication distributed on August 31<sup>st</sup> of the corresponding year.**

### NOTICE –INTERESTED PARTY PROCESS

Upon review of this agenda, if the reviewer believes that they will need to provide comment on an issue, they must seek Interested Party status by [submitting a request](#) for a copy of the application and associated materials. **Requests are to be submitted through the Smart App's CPT Interested Party dashboard.** Those interested in review of the agenda materials are required to complete this form in full.

Any interested parties wishing to provide written comments on any agenda items should be aware of the following relevant deadlines for provision of written comments on the agenda to ensure comment review by all parties. Additional verbal comments on any issue can be provided in person at the Panel meeting following a statement of conflict of interest. The applicant(s) who submitted the original code change application is automatically considered an interested party and is notified by AMA staff of any request for review submitted by another party.

Updated November 14, 2025

- New
- ▲ Revision
- ⊕ Add on
- D Deletion

\*Interested party requests will not be processed until the interested party submits a signed confidentiality agreement and disclosure of interest form. Please follow the instructions in the correspondence that accompanies the materials.

Issues	Tabs	Deadline to Request Materials *NEW: you may request materials through Friday of the Panel Meeting.	Comments Deadline (Noon, CST) for Path/Lab
Path/Lab	18-29, 45	-----	Dec. 1, 2025

During the time between now and the Panel meeting, this listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP CCAs may be modified to reflect changes – additions, deletions or updates. Please check back frequently for the most up to date information. Outcomes on these actions will be listed in the CPT Editorial Panel Summary of Actions for the February 2026 meeting, which will be published on February 20, 2026 to the CPT home page of the AMA website <http://www.ama-assn.org/go/panel-actions>.

	Name	Code #	Request-Description
18	MoPath Tier 2-RBM20	▲81406	Revise code 81406 to include testing for RBM20.
19	MoPath Tier 2-COL3A1	▲81408	Revise code 81408 to include testing for COL3A1.

Updated November 14, 2025

● New  
▲ Revision  
+ Add on  
D Deletion

	Name	Code #	Request-Description
20	MoPath Tier 2-SMAD3	▲81406	Revise code 81406 to include testing for SMAD3.
21	GSP-Genetic Testing-Heritable Renal Conditions	●8XX18	Establish code 8XX18 to report genetic testing for heritable renal conditions.
22	GSP-Complement-Mediated TMA-C3G Gene Panels for Renal Disorders	●8XX22	Establish code 8XX22 to report heritable, complement-mediated renal disorder genetics testing Panels (TMA, C3G).
23	MAAA-pTau-217-Aβ1-42 Ratio for Alzheimer's Testing	●8XX23	Establish code 8XX23 for ptau-217/beta-amyloid and 1-42 plasma testing as a ratio for analyzing Alzheimer's.

	Name	Code #	Request-Description
24	Osteopontin-c IHC- Revise 88360	▲88360	Revise code 88360 to identify intercellular cytokines as an example for morphometric analysis tumor IHC for breast cancer prediction.
25	Mycoplasma Species Resistance	●87XX2	Establish code 87XX2 to report Mycoplasma species resistance.
26	Mycoplasma Genitalium ID and Resistance	●87XX3	Establish code 87XX3 to report Mycoplasma genitalium resistance.
27	Cell-free DNA HPV Assay	●87XX4	Establish code 87XX4 to report a molecular diagnostic assay that detects high-risk human papillomavirus (HPV) DNA in circulating cell-free DNA (cfDNA) extracted from plasma.

Updated November 14, 2025

● New  
▲ Revision  
+ Add on  
D Deletion

	Name	Code #	Request-Description
28	MAAA-Bacterial Vaginitis RNA Markers	● 8XX20	Establish a Category I Multianalyte Assays with Algorithmic Analyses (MAAA) code 8XX20 for infectious disease testing for bacterial vaginosis and vaginitis using quantitative real-time amplification of RNA markers.
29	Cell Purification-Immunomagnetic Beads Technique	● 8XX21	Establish Category I code 8XX21 to report immunomagnetic beads-based cell sorting of specific (target) cell populations prior to downstream testing.
45	Cat III-AI Response to Immunotherapy-Bladder (NMIBC)	● X568T ● X569T	Request to establish Cat III codes X568T, X569T to report use of AI to provide autonomous algorithmic image analysis of FFPE bladder cancer tissue for BCG treatment success for cancer